• Novartis radiopharmaceutical improves survival in key prostate cancer study

    15 days ago - By MedCity News

    Novartis reported Phase 3 study results for a targeted radiation therapy showing that treatment helped patients with advanced prostate cancer live longer. The company will present data from this pivotal study during the annual meeting of the American Society of Clinical Oncology.
    Read more ...